NORD Launches Financial Assistance Programs for MG Patients in US
The National Organization for Rare Disorders (NORD), a nonprofit organization dedicated to supporting those with rare diseases, has launched…
Articles by Joana Carvalho, PhD
Argenx Files for FDA Approval of Efgartigimod for Generalized MG
Argenx has filed an application to the U.S. Food and Drug Administration (FDA) requesting the approval of…
Age at Disease Onset, Exercise Among Factors Seen to Affect Patients’ Life Quality
Quality of life tends to be poorer in people with myasthenia gravis (MG) who develop the disease later in…
Older MG Patients on IVIG May Have Higher Risk of Coronary Spastic Angina
Older patients with myasthenia gravis (MG) who receive treatment with intravenous immunoglobulin (IVIG) may be at a higher…
Johnson & Johnson to Acquire Momenta and Rights to Nipocalimab
Johnson & Johnson will acquire Momenta Pharmaceuticals, which has been developing nipocalimab (M281) for the treatment of myasthenia…
Protein May Be Biomarker to Help Identify Difficult-to-diagnose MG, Study Says
High levels of kappa free light chain — a protein that makes up a portion of immunoglobulins (antibodies)…
Case Supports Soliris as Promising Treatment for Thymoma-associated MG
Soliris (eculizumab) may be a promising treatment option for patients with refractory myasthenia gravis (MG) associated with…
Immunovant Prepares to Launch Phase 3 Trial of IMVT-1401 in MG Patients
Immunovant is preparing to launch a Phase 3Â trial of its investigational candidate IMVT-1401 in patients with myasthenia gravis…
Mitochondria Defects in Immune Cells May Cause MG, Study Says
Defects in mitophagy — the process that degrades defective mitochondria, the cell compartments responsible for producing energy —…
Rituximab More Beneficial if Given to gMG Patients Early, Study Finds
Rituximab seems to be more effective in newly-diagnosed patients with generalized myasthenia gravis (gMG), compared to people at…